Structure Therapeutics Inc. American Depositary Shares (GPCR · NASDAQ)

GPCR · MARKET VIEW

Market view · as of Jul 27, 2026

Revenue (TTM)
$0
0.0% YoY
EPS (latest q)
$-0.35
vs $-0.33 est · miss
52-wk position
42.4%
-47.6% vs 52w high · +1.8% 1mo

Price (last ~year)

Clinical-stage biopharmaceutical firm Structure Therapeutics (GPCR) faces a patent dispute concerning its oral GLP-1 weight-loss drug compounds. The company, which maintains a $3.49 billion market capitalization, reported $0 revenue and a $76.2 million net loss for the quarter ending March 31, 2026. With $316.2 million in cash and $5.8 million in total debt, shares closed at $49.12, down 3.3% on the day.

Valuation

Market cap
$3.49B
P/B
2.413
EV/EBITDA
-13.46
Beta
-1.569
Analyst target
$104.83

Quality & returns

Operating margin
0.0%
Profit margin
0.0%
ROE
-15.0%
ROA
-11.6%

Price movement

Last
$49.12
1-month
+1.8%
3-month
+12.8%
RSI (14)
37
vs SMA200
-4.6%
52-wk position
42.4% -47.6% vs high

Quarterly trajectory

Revenue by quarter (oldest → newest)

QuarterRevenueOp incomeNet incomeEBITDA
2026-03-31$0$-89.6M$-76.2M$-74.8M
2025-12-31$0$24.0M$33.0M$33.6M
2025-09-30$0$-73.8M$-65.7M$-65.3M
2025-06-30$0$-70.5M$-61.7M$-61.2M

Recent news

Sources this view read

  • fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
  • filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
  • earnings Reported earnings history (Alpha Vantage EARNINGS)
  • prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)

Other snapshots